Gevo (NASDAQ:GEVO) Files An 8-K Results of Operations and Financial Condition

0

Gevo (NASDAQ:GEVO) Files An 8-K Results of Operations and Financial Condition
Item 9.01. Results of Operations and Financial Condition.

As of June 22, 2018, the Companyhad cash and cash equivalents of approximately $19.8 million. This amount is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s financial condition as of June 22, 2018. The review of the Company’s financial statements for the quarter ending June 30, 2018 has not begun and could result in changes to this amount.

Item 9.01.Unregistered Sales of Equity Securities.

The information provided in Item 9.01 of this Current Report on Form 8-K is incorporated by reference into this Item 9.01.

Item 9.01.Other Events.

Partial Conversion of 2020 Notes

On June 19, 2018 and June 21, 2018, the Company received conversion notices from the holders of its 12.0% convertible senior secured notes due 2020 (the “2020 Notes”) to convert an aggregate of approximately $3.2 million in aggregate principal amount of 2020 Notes for an aggregate of 260,793 shares of the Company’s common stock at a conversion rate of 0.0679 shares of common stock per $1 principal amount of 2020 Notes. Upon completion, these conversions reduced the outstanding principal amount of the 2020 Notes to approximately $13.55 million. The Company expects that the holders of its 2020 Notes may continue to convert the outstanding 2020 Notes into the Company’s common stock in the future from time to time based on market conditions.

Exercise of Series K Warrants

During June 2018, the Company received notices of exercise from holders of its Series K warrants to purchase common stock (the “Series K Warrants”) to issue an aggregate of 295,456 shares of common stock for total gross proceeds of approximately $1.24 million. Following these exercises, Series K Warrants to purchase 9,060 shares of common stock remain outstanding at an exercise price of $4.20 per share.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

1.1

At-The-Market Offering Agreement, dated February 13, 2018, between Gevo, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.1 of the Current Report on Form 8-K filed on February 13, 2018).

1.2

Amendment to At-The-Market Offering Agreement and Engagement Agreement, dated June 20, 2018, between Gevo, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 of the Current Report on Form 8-K filed on June 20, 2018).

1.3

Amendment to At-The-Market Offering Agreement, dated June 25, 2018, betweenGevo, Inc. and H.C. Wainwright & Co., LLC.

5.1

Opinion of Perkins Coie LLP, with respect to the legality of the securities being registered.

23.1

Consent of Perkins Coie LLP (contained in Exhibit 5.1 hereto).


Gevo, Inc. Exhibit
EX-1.3 2 ex_116855.htm EXHIBIT 1.3 ex_116855.htm Exhibit 1.3     June 25,…
To view the full exhibit click here

About Gevo (NASDAQ:GEVO)

Gevo, Inc. (Gevo) is a renewable chemicals and next generation biofuels company. The Company has developed a technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstock. It has two operating segments: the Gevo, Inc. segment and the Gevo Development/Agri-Energy segment. Its Gevo, Inc. segment is responsible for research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Its Gevo Development/Agri-Energy segment is responsible for the operation of its Agri-Energy Facility and the production of ethanol, isobutanol and related products.